Phaseline

Targets › NTSR1

NTSR1 (Neurotensin receptor type 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jul 2030.

G protein-coupled receptor for the tridecapeptide neurotensin (NTS). Signaling is effected via G proteins that activate a phosphatidylinositol-calcium second messenger system. (UniProt, P30989)

Open in Phaseline: the race on NTSR1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
SK Life ScienceSKL35501
NTSR1-targeting small molecule linked to alpha emitter 225Ac
NTSR1Phase 1Selected Advanced Solid TumorsJul 2030

Conditions

Selected Advanced Solid Tumors (1)

Modalities

small molecule (1)

Companies

SK Life Science (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.